ParkinsonCanadaV1, Main, Exploration, bibRecord, 002699

A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities

Identifieur interne : 002699 ( Main/Exploration ); précédent : 002698; suivant : 002700

A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities

Auteurs : Murray M. Finkelstein [Canada] ; Michael Jerrett [États-Unis]

Source :

Environmental research : (New York, N.Y. : Print) [ 0013-9351 ] ; 2007.

RBID : Pascal:07-0357748

Descripteurs français

Pascal (Inist)
- Environnement, Manganèse, Pollution air, Canada, Milieu urbain, Homme, Parkinson maladie, Trafic routier urbain, Toxicité, Epidémiologie, Gaz échappement, Industrie, Santé publique.
Wicri :
- geographic : Canada.
- topic : Manganèse, Homme, Santé publique.

English descriptors

KwdEn :
- Adult, Aged, Air Pollutants (analysis), Air Pollutants (toxicity), Air pollution, Antiparkinson Agents (therapeutic use), Canada, Canada (epidemiology), Case-Control Studies, Cities, Cohort Studies, Environment, Epidemiology, Exhaust gas, Human, Humans, Industry, Levodopa (therapeutic use), Manganese, Manganese (analysis), Manganese (toxicity), Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson Disease (etiology), Parkinson Disease (pathology), Parkinson disease, Public health, Toxicity, Urban environment, Urban road traffic, Vehicle Emissions (analysis), Vehicle Emissions (toxicity).
MESH :
- chemical , analysis : Air Pollutants, Manganese, Vehicle Emissions.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- chemical , toxicity : Air Pollutants, Manganese, Vehicle Emissions.
- geographic , epidemiology : Canada.
- drug therapy : Parkinson Disease.
- epidemiology : Parkinson Disease.
- etiology : Parkinson Disease.
- pathology : Parkinson Disease.
- Adult, Aged, Case-Control Studies, Cities, Cohort Studies, Humans, Middle Aged.

Abstract

There is concern that industrial emissions of manganese (Mn) and the use of Mn-containing compounds as fuel additives might increase the population risk of Parkinson's disease (PD)-like disorders. We investigated associations between the diagnosis and treatment of PD and markers of exposure to vehicle exhaust and industrial emissions of Mn within a cohort of 110,000 subjects in the cities of Toronto and Hamilton, Canada. Methylcyclopentadienyl manganese tricarbonyl (MMT) has been added to Canadian gasoline since 1976 and steelmaking in Hamilton emits Mn to the air. Using residential postal codes, subjects were mapped to: (1) residence locations close to traffic and to neighbourhood levels of NO₂, as markers of traffic-generated air pollution (TGAP); and, (2) neighbourhood levels of ambient Mn in Hamilton, as measured by the Mn fraction of total suspended particulate. Subjects were linked to Ministry of Health administrative databases, 1992-1999, to identify physicians' diagnoses of PD and prescriptions for L-Dopa containing medications. In Toronto, we found no association between PD and the markers of TGAP. In Hamilton, the odds ratio for a physician's diagnosis of PD was 1.034 (1.00-1.07) per 10 ng/m³ increase in Mn in TSP. The estimate of the "doubling exposure" for physician-diagnosed PD was about 150 ng/m³ Mn in TSP. Examination of prevalence curves suggested that exposure to ambient Mn advances the age of diagnosis of PD, consistent with the theory that exposure to Mn adds to the natural loss of neurons attributable to the aging process.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities</title>
<author><name sortKey="Finkelstein, Murray M" sort="Finkelstein, Murray M" uniqKey="Finkelstein M" first="Murray M." last="Finkelstein">Murray M. Finkelstein</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McMaster University and University of Toronto</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>McMaster University and University of Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jerrett, Michael" sort="Jerrett, Michael" uniqKey="Jerrett M" first="Michael" last="Jerrett">Michael Jerrett</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>University of California</s1>
<s2>Berkeley</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Berkeley (Californie)</settlement>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0357748</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0357748 INIST</idno>
<idno type="RBID">Pascal:07-0357748</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000721</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000599</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000676</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000676</idno>
<idno type="wicri:doubleKey">0013-9351:2007:Finkelstein M:a:study:of</idno>
<idno type="wicri:Area/Main/Merge">002966</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17445792</idno>
<idno type="wicri:Area/PubMed/Corpus">001058</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001058</idno>
<idno type="wicri:Area/PubMed/Curation">001058</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001058</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001058</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001058</idno>
<idno type="wicri:Area/Ncbi/Merge">000757</idno>
<idno type="wicri:Area/Ncbi/Curation">000757</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000757</idno>
<idno type="wicri:doubleKey">0013-9351:2007:Finkelstein M:a:study:of</idno>
<idno type="wicri:Area/Main/Merge">002733</idno>
<idno type="wicri:Area/Main/Curation">002699</idno>
<idno type="wicri:Area/Main/Exploration">002699</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities</title>
<author><name sortKey="Finkelstein, Murray M" sort="Finkelstein, Murray M" uniqKey="Finkelstein M" first="Murray M." last="Finkelstein">Murray M. Finkelstein</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McMaster University and University of Toronto</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>McMaster University and University of Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jerrett, Michael" sort="Jerrett, Michael" uniqKey="Jerrett M" first="Michael" last="Jerrett">Michael Jerrett</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>University of California</s1>
<s2>Berkeley</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Berkeley (Californie)</settlement>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Environmental research : (New York, N.Y. : Print)</title>
<title level="j" type="abbreviated">Environ. res. : (N.Y. N.Y. : Print)</title>
<idno type="ISSN">0013-9351</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Environmental research : (New York, N.Y. : Print)</title>
<title level="j" type="abbreviated">Environ. res. : (N.Y. N.Y. : Print)</title>
<idno type="ISSN">0013-9351</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Air Pollutants (analysis)</term>
<term>Air Pollutants (toxicity)</term>
<term>Air pollution</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Canada</term>
<term>Canada (epidemiology)</term>
<term>Case-Control Studies</term>
<term>Cities</term>
<term>Cohort Studies</term>
<term>Environment</term>
<term>Epidemiology</term>
<term>Exhaust gas</term>
<term>Human</term>
<term>Humans</term>
<term>Industry</term>
<term>Levodopa (therapeutic use)</term>
<term>Manganese</term>
<term>Manganese (analysis)</term>
<term>Manganese (toxicity)</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson Disease (etiology)</term>
<term>Parkinson Disease (pathology)</term>
<term>Parkinson disease</term>
<term>Public health</term>
<term>Toxicity</term>
<term>Urban environment</term>
<term>Urban road traffic</term>
<term>Vehicle Emissions (analysis)</term>
<term>Vehicle Emissions (toxicity)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Air Pollutants</term>
<term>Manganese</term>
<term>Vehicle Emissions</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Air Pollutants</term>
<term>Manganese</term>
<term>Vehicle Emissions</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Case-Control Studies</term>
<term>Cities</term>
<term>Cohort Studies</term>
<term>Humans</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Environnement</term>
<term>Manganèse</term>
<term>Pollution air</term>
<term>Canada</term>
<term>Milieu urbain</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Trafic routier urbain</term>
<term>Toxicité</term>
<term>Epidémiologie</term>
<term>Gaz échappement</term>
<term>Industrie</term>
<term>Santé publique</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Manganèse</term>
<term>Homme</term>
<term>Santé publique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There is concern that industrial emissions of manganese (Mn) and the use of Mn-containing compounds as fuel additives might increase the population risk of Parkinson's disease (PD)-like disorders. We investigated associations between the diagnosis and treatment of PD and markers of exposure to vehicle exhaust and industrial emissions of Mn within a cohort of 110,000 subjects in the cities of Toronto and Hamilton, Canada. Methylcyclopentadienyl manganese tricarbonyl (MMT) has been added to Canadian gasoline since 1976 and steelmaking in Hamilton emits Mn to the air. Using residential postal codes, subjects were mapped to: (1) residence locations close to traffic and to neighbourhood levels of NO<sub>2</sub>
, as markers of traffic-generated air pollution (TGAP); and, (2) neighbourhood levels of ambient Mn in Hamilton, as measured by the Mn fraction of total suspended particulate. Subjects were linked to Ministry of Health administrative databases, 1992-1999, to identify physicians' diagnoses of PD and prescriptions for L-Dopa containing medications. In Toronto, we found no association between PD and the markers of TGAP. In Hamilton, the odds ratio for a physician's diagnosis of PD was 1.034 (1.00-1.07) per 10 ng/m<sup>3</sup>
 increase in Mn in TSP. The estimate of the "doubling exposure" for physician-diagnosed PD was about 150 ng/m<sup>3</sup>
 Mn in TSP. Examination of prevalence curves suggested that exposure to ambient Mn advances the age of diagnosis of PD, consistent with the theory that exposure to Mn adds to the natural loss of neurons attributable to the aging process.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
</region>
<settlement><li>Berkeley (Californie)</li>
</settlement>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Finkelstein, Murray M" sort="Finkelstein, Murray M" uniqKey="Finkelstein M" first="Murray M." last="Finkelstein">Murray M. Finkelstein</name>
</noRegion>
</country>
<country name="États-Unis"><region name="Californie"><name sortKey="Jerrett, Michael" sort="Jerrett, Michael" uniqKey="Jerrett M" first="Michael" last="Jerrett">Michael Jerrett</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002699 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002699 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:07-0357748
   |texte=   A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities

A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.